CryoLife, Inc, a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of Jotec AG, a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair.
The deal was first announced in October.
Jotec generated revenue of approximately €41 million in 2016, representing compound annual growth of approximately 17% over the preceding five years. Jotec generated revenues of €43 million for the twelve months ended 30 June, 2017.
